Welcome : Guest

Press Release


MCP-1028: BLOOD BANKING AND BLOOD PRODUCTS – A GLOBAL STRATEGIC BUSINESS REPORT

April 20, 2017 – Increase in Disease Burden & Commercialization of Blood Donation Drive Growth in the Global Blood Banking & Blood Products Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Blood Banking and Blood Products market. The global market for Blood Banking and Blood Products is projected to reach US$45.8 billion by 2022, driven by the rising disease burden and a parallel increase in demand for immunoglobulins and plasma derivatives, and commercialization of blood donation and the resulting establishment of wide networks of collection agencies dependent on paid donations.

The global market for blood banking and blood products is exhibiting healthy trend owing to the aging population, rise in chronic diseases and steep rise in healthcare expenditures. Regulatory and healthcare bodies across the world are adopting stringent policies relating to blood safety, and hence manufacturers the world over are developing improved, safer, and advanced blood-banking technologies for collection, processing and delivery of blood products. The growth in the market is also driven by factors such as technological advancements and the advent of innovative products, increased disease diagnosis rates and well as new emergence of new therapies including apheresis therapy, better pricing environment for blood proteins in some markets and the strong promotional campaigns undertaken by various collection agencies for encouraging blood donation. In addition, the growing popularity of synthetic blood products is driving growth in the blood processing market. Epidemic rise in cancer and the ensuing spurt in its treatment procedures and rapid increase in complex surgical procedures such as open heart and orthopedic surgeries also bode well for market growth.

Owing to its rich composition and versatile functions, plasma continues to be the major blood component as it also serves as a liquid exchange medium for body fluid, hormones, antibodies, nutrients, and numerous proteins including immunoglobulin and albumin. The outlook for plasma derivatives remains positive, with major plasma products such as immunoglobulins, alpha 1 and albumin expected to witness sizable growth in the near term. Recombinants dominate the hematology market with a two-thirds share, while phasmatic accounts for the rest. Major indications include Hemophilia A and Inhibitor bleed therapy. Plasma-derived FVIII has grown at a low single-digit growth over the past three decades, while recombinants grew at a sizably higher rate. Ensuring product safety is one of the major challenges for the blood and blood banking industry, particularly with blood transfusion being a significant channel for transmitting dangerous infections such as HIV. To deal with this, companies across the globe are developing simple, safe, affordable, effective, and reliable technologies to reduce the risk of blood transfusion by inactivating and reducing a wide range of pathogens, without damaging the components of blood products.

As stated by the new market research report on Blood Banking and Blood Products, the United States represents the largest market worldwide supported by well-developed and coordinated healthcare infrastructure; high standard of care; favorable reimbursement policies; adoption of advanced technologies; and government support. Asia-Pacific is poised to record the fastest CAGR of 8.1% over the analysis period, led by growing population and healthcare burden; rising standards of living, increasing disposable income and growing per capita healthcare spending; huge unmet patient needs and largely underserved blood services; development of public and private healthcare infrastructure including establishment of blood services networks and banks; and rise in medical tourism in low cost Asian countries.

Major blood banks covered in the report include AABB, America’s Blood Centers, American Red Cross, Canadian Blood Services, Japan Red Cross Society, New York Blood Center, Sanquin Blood Supply Foundation. The report also profiles leading players of blood bank technology/ supplies and plasma fractionation that include Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Cerus Corporation, CSL Behring LLC, Fresenius Kabi AG, Fenwal Inc., Haemonetics Corporation, Immucor Inc., Kawasumi Laboratories, Inc., MacoPharma SA, Ortho-Clinical Diagnostics, Inc., Terumo BCT Inc., Beijing Tiantan Biological Products Co., Ltd., Bharat Serums and Vaccines Ltd., Bio Products Laboratory Ltd., Biotest AG, China Biologic Products, Inc., Grifols S.A., Huanlan Biological Engineering Inc., Kedrion S.p.A., LFB Group, Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Shire plc, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., among others.

The research report titled “Blood Banking and Blood Products: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections in US$ Millions for all major geographic markets such as US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific (China, and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America), and Rest of World. The report also provides volume analytics (in units) for the global market for Blood Components & Plasma Products; and Red Blood Cells.

 

» View Complete Report Details

« Back